Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Assets (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Non-Current Assets for 3 consecutive years, with $22.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Assets fell 59.58% year-over-year to $22.3 million, compared with a TTM value of $22.3 million through Sep 2024, down 59.58%, and an annual FY2023 reading of $58.0 million, up 1178.78% over the prior year.
  • Non-Current Assets was $22.3 million for Q3 2024 at Oramed Pharmaceuticals, down from $31.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $58.0 million in Q4 2023 and bottomed at $4.3 million in Q3 2022.
  • Average Non-Current Assets over 3 years is $24.3 million, with a median of $26.6 million recorded in 2024.
  • Peak annual rise in Non-Current Assets hit 1193.97% in 2023, while the deepest fall reached 83.87% in 2023.
  • Year by year, Non-Current Assets stood at $4.5 million in 2022, then skyrocketed by 1178.78% to $58.0 million in 2023, then tumbled by 61.52% to $22.3 million in 2024.
  • Business Quant data shows Non-Current Assets for ORMP at $22.3 million in Q3 2024, $31.0 million in Q2 2024, and $26.6 million in Q1 2024.